Answer
Clinical interaction studies found no clinically relevant change in fulvestrant clearance with rifampicin or ketoconazole, so no fulvestrant dose adjustment is necessary with concomitant CYP3A4 inducers or inhibitors.
Sources for this answer
- Faslodex 250 mg solution for injectionAstraZeneca UK Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 28Document updated
Sources checked